Cardiff Oncology, Onvansertib, FDA, Orphan Drug Designation, Chronic Myelomonocytic Leukemia, CMML, PLK1 Inhibitor, Hematologic Malignancy,

SAN DIEGO, Calif. — October 21, 2026 Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company developing cancer therapies...